Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial complex I (NADH:ubiquinone oxidoreductase) and mitochondrial glycerophosphate dehydrogenase (mGPDH) are critical enzymes involved in cellular energy metabolism and redox balance (UniProt P03886, P43304). Complex I is the first and largest component of the mitochondrial electron transport chain, responsible for oxidizing NADH and contributing to the proton gradient for ATP production (PubMed: 10839993). mGPDH is a key component of the glycerol-3-phosphate shuttle, which transfers reducing equivalents from the cytosol to the mitochondria, thereby maintaining the cytosolic NAD+/NADH ratio (Nature: 24847880). Together, these targets play a pivotal role in regulating hepatic gluconeogenesis and systemic glucose levels. Drugs like metformin inhibit these enzymes to alter the NADH/NAD+ ratio and increase cellular AMP levels, which suppresses glucose production in the liver (Nature: 24847880). This dual inhibition is a primary mechanism for treating type 2 diabetes and is being explored for potential anti-cancer applications due to its impact on cellular bioenergetics (PubMed: 27508874). While Complex I inhibition is a well-established effect of biguanides, the specific role of mGPDH inhibition has emerged as a significant contributor to the suppression of gluconeogenesis from lactate and glycerol (Nature: 24847880). Therapeutic modulation of these targets requires careful management to avoid excessive inhibition, which can lead to metabolic complications such as lactic acidosis (PubMed: 20371550).
Inhibition of mitochondrial respiratory chain Complex I and mitochondrial glycerophosphate dehydrogenase leads to a decrease in hepatic gluconeogenesis by altering the cytosolic and mitochondrial redox states and increasing the AMP:ATP ratio, which subsequently activates AMP-activated protein kinase (AMPK) (Nature: 24847880; PubMed: 10839993).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial complex I and mitochondrial glycerophosphate dehydrogenase (Complex I/mGPDH).